Multiple biochemical tumor markers in seminoma. A double-blind study.
The value of certain biochemical tumor markers have been well established in nonseminomatous testicular cancer. However, the lack of frequent tumor markers in the sera of patients with seminoma has prompted us to embark on this double blind study. The authors studied 89 patients with the histologic diagnosis of seminoma utilizing placental alkaline phosphatase (PLAP), gamma-glutamyl transpeptidase (gamma GT), human chorionic gonadotropin (hCG), and alpha-fetoprotein (AFP). It was found that 12/30 patients (40%) with active tumor had elevated serum PLAP and 10/30 (33%) of these patients had elevated serum levels of GGT. Eighty percent of the patients with clinically active tumors had detectable serum levels of one or more of these biochemical markers. Since the frequency of the previous tumor markers have been scarce in seminoma, these serial utilization of these biochemical markers should assist the clinician to detect and monitor seminoma patients more efficaciously. However, the false-positive, false-negative, rates, and biologic half lifes of these markers should be taken in account.
D000469:Alkaline Phosphatase / Q000097:blood*; D002369:Castration; D006063:Chorionic Gonadotropin / Q000097:blood; D003951:Diagnostic Errors; D004311:Double-Blind Method; D004407:Dysgerminoma / Q000097:blood*; D006801:Humans; D008297:Male; D010920:Placenta / Q000201:enzymology; D011336:Probability; D013736:Testicular Neoplasms / Q000097:blood*; D005723:gamma-Glutamyltransferase / Q000097:blood*
D006063:Chorionic Gonadotropin; D005723:gamma-Glutamyltransferase; D000469:Alkaline Phosphatase